Langdon et al. showed that mTOR signaling was inhibited at an early stage with a dual PI3K/mTOR inhibitor, indicating that the dual-targeted inhibitor only prevented cancer progression, and cancer cells still remained viable and could not be treated [40]. The gene discussed is PIK3CA; the disease is cancer.